Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

Abstract Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors rarely elicit complete responses in patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC), as a small population of tumor cells survives due to adaptive resistance. Therefore, we focused on the mechanisms underly...

Full description

Bibliographic Details
Main Authors: Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Shinsaku Tokuda, Kenji Morimoto, Soichi Hirai, Yohei Matsui, Ryota Nakamura, Masaki Ishida, Hayato Kawachi, Kazue Yoneda, Kazutaka Hosoya, Takahiro Tsuji, Hiroaki Ozasa, Akihiro Yoshimura, Masahiro Iwasaku, Young Hak Kim, Mano Horinaka, Toshiyuki Sakai, Takahiro Utsumi, Shinsuke Shiotsu, Takayuki Takeda, Ryohei Katayama, Koichi Takayama
Format: Article
Language:English
Published: Nature Portfolio 2023-01-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-023-00350-7

Internet

https://doi.org/10.1038/s41698-023-00350-7

Similar Items